The study of pregnancy and motherhood in women living with HIV (WLWH) has concentrated on the health of the unborn baby and the prevention of mother-to-child transmission, whereas consideration of the broader aspects of women's reproductive health has been largely overlooked. The rights of WLWH with respect to their reproductive health should be exactly the same as non-HIV-positive women, however, inequalities exist due to discrimination and also because the treatment guidelines used in the care of women are often based on insufficient evidence. The purpose of this article is to review the available literature on reproductive health issues for WLWH and to identify gaps requiring further investigation. Our review indicates that further research is warranted into a number of aspects of reproductive health among WLWH. Currently, access to the relevant reproductive health resources and services, such as advice on contraception and fertility services, for WLWH is far from optimal in many developed countries and most developing countries. More data are needed on the most appropriate family planning options with the consideration of drug interactions between contraceptives and antiretroviral therapy and the risk of HIV transmission. Also, more research is needed to improve understanding of the maternal health challenges facing WLWH. Similarly, our understanding of the impact of HIV on the physical and emotional health of pregnant women and new mothers is far from complete. Answering these questions and countering these inequalities will help to ensure the reproductive health and child-bearing intentions of WLWH become an integral part of HIV medicine.
Introduction
While three million women living with HIV (WLWH) give birth each year (UNAIDS, 2010) , the clinical guidance on reproductive health in this group has concentrated primarily on the health of the unborn baby and the prevention of mother-to-child transmission (MTCT) rather than on the expectant mother's health. Effective antiretroviral therapy (ART) has reduced MTCT and is less of a concern. With the majority of WLWH being of childbearing-age, reproductive health and rights and access to reproductive care have become important global issues but data are lacking. The purpose of this article is to review existing research and guidance on preconception considerations, contraception, maternal health and post-partum issues for WLWH, and to identify gaps in this evidence that require further investigation.
Methods
This article was written using scoping review methodology (Arksey & O'Malley, 2005) to provide a narrative account of available research into preconception, contraception, maternal health and postpartum issues in WLWH. MEDLINE was searched for articles from 1950 to 2012 using diverse MeSH headings relevant to reproductive health in WLWH (Appendix). Relevant bibliographies, existing networks and HIV organisations, guidelines and conference abstracts were also reviewed, and experts in the field consulted regarding missing publications. Abstracts were scanned to determine if they were relevant to reproductive health in WLWH and to eliminate those focusing on the health of the unborn baby or the prevention of MTCT, before the full articles were reviewed. The quality of guidelines was assessed using the appraisal of guidelines for research and evaluation instrument (Brouwers et al., 2010) .
Preconception considerations
Studies, including the meta-analysis by Nattabi, Li, Thompson, Orach, and Earnest (2009) , have reported that between 26% and 57% of WLWH intend to have children (Loutfy et al., 2009; Ogilvie et al., 2007) . WLWH share the same rights as other women in terms of pregnancy and motherhood, but to fulfil these, access to general reproductive, preconception, pregnancy and post-partum counselling should be made to be a part of routine HIV care. This should include discussions about optimising HIV management, standard prenatal counselling, including healthy lifestyle advice, suitable conception options (Table 1) , ART for the prospective mother and, potentially, child, as well as adoption and fertility options. An individual or couple should be referred for fertility assessment if there is no conception after 3Á12 months (or earlier if the woman is 35 years). Access to these services and costs vary geographically. In addition, access to adoption services can be limited, depending on country (Table 2) .
There is a lack of information about conception planning and pregnancy for those wishing to have children (Huynh et al., 2012) . Ndlovu et al. (2009) found evidence of inadequate knowledge among people living with HIV (PLWHIV) about pregnancy, despite having regular access to a healthcare professional, and reported that ethnicity influenced the degree of knowledge. PLWHIV and healthcare providers globally have indicated that access to clinical guidelines, pamphlets, workshops and peer-counselling and support are important tools to optimise the care of PLWHIV during preconception and conception (Fakoya et al., 2008; Huynh et al., 2012) . Preconception and conception guidelines currently available across Europe, Canada and USA are outlined in Table 2 .
Family planning and contraception
Among WLWH, the proportion of unintended pregnancies is high at 50Á83% (Floridia et al., 2006; Koenig, Espinoza, Hodge, & Ruffo, 2007; Loutfy et al., 2012a) . Tailored reproductive counselling and contraception discussions early in the course of HIV care are crucial for all women to prevent unintended pregnancies. A variety of contraceptive options are available (Table 3 ) and the choice should take into account potential interactions with ART (Table 4) . A recent study has reported that women using hormonal contraceptives, specifically depot medroxyprogesterone acetate (DMPA), had twice the risk of acquiring or transmitting HIV as other women (Heffron et al., 2012 (1) the use of hormonal contraceptives, including COC, POP, DMPA and implants, are safe for women at high risk for HIV infection or infected with HIV and (2) all women who use contraceptive methods other than condoms should be counselled regarding the use of condoms and the risk for sexually transmitted infections (STIs; Tepper, Curtis, Jamieson, & Marchbanks, 2012) . However, a clarification is added to the recommendation for women at high risk for HIV infection who use DMPA or norethisterone enantate to acknowledge the inconclusive evidence regarding the association between progestin-only injectable use and HIV acquisition. Since condoms are poor at preventing pregnancy, but required to prevent HIV and STIs, dual protection including a hormonal contraceptive (or copper intrauterine device) and a condom is recommended (Department of Health and Human Services [DHHS], 2011a; WHO, 2012) .
Maternal health, HIV and pregnancy
Complications during childbirth lead to the death of one woman every minute (approximately 529,000 each year) (UNICEF, 2009). Prior to combination ART, pre-eclampsia was an uncommon complication of pregnancy in WLWH (Stratton et al., 1999) . Although the benefits of taking ART during pregnancy outweigh the risks, the incidence of preeclampsia has now risen to a rate similar to that reported among the general population (European Collaborative Study, 2003; Wimalasundera et al, 2002) and the mother should be closely monitored (Lopez et al., 2012) . Limited data show a higher prevalence of gestational diabetes in WLWH (2Á5% in industrialised countries) compared with the general population (Gonza´lez-Tome´et al., 2008) . However, the risk factors in WLWH are largely unclear and the data are contradictory (Watts et al., 2004) .
Current guidance on whether ART should be continued or stopped in WLWH with CD4 counts 500 cells/mm 3 following delivery remain unclear and data from ongoing trials are awaited. However, treatment interruptions guided by CD4 cell counts appear to put PLWHIV at an increased risk of disease progression (Strategies for Management of Antiretroviral Therapy [SMART] Study Group et al., 2006) , and there is a trend towards an increased risk of AIDS or all-cause mortality in women who stopped taking ART within 90 days of delivery (Melekhin et al., 2010) . Recent UK guidelines recommend that when stopping non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART post-partum the NNRTI washout period should be covered by two weeks of protease inhibitor (PI)-based therapy (de Ruiter et al., 2012) . Cessation of maternal ART in the first year afterbirth has little effect on CD4 levels, but it does have an effect on immune activation (Watts et al., 2009 ). Considerations of adherence, the overall health of the mother, and her readiness to continue treatment during the post-partum phase need to be assessed on an individual basis, in collaboration with the mother.
Perinatal and post-partum considerations
Perinatal depression refers to depression occurring during pregnancy or up to one-year after the birth and includes post-partum depression. Perinatal depression is a common phenomenon (Kapetanovic et al., 2009) . In a review from Gaynes et al. (2005) , the prevalence of major depression during pregnancy and post-partum ranged from 3.1% to 4.9% and 1.0% to 5.9%, respectively. As PLWHIV are more likely to suffer from depression, WLWH may be at an even higher risk of perinatal depression (Herbert & Cohen, 1993; Sherr, Clucas, Harding, Sibley, & Catalan, 2011) . Factors that may contribute to increased perinatal depression in WLWH include maternal guilt, fear of transmitting HIV to the newborn, concerns related to disclosure, stigma and the negative impacts of maternal HIV on their children, preconception substance use, multiple preconception sexual partners, lower socio-economic status, medication adherence problems, multiparity, lower CD4 pregnancy nadir and impaired physical and cognitive functioning (Chibanda et al., 2010; Greene et al., 2009; Kapetanovic et al., 2009; Leonard, 1998; Morrison et al., 2002; Parsons, Young, Rochat, Kringelbach, & Stein, 2012; Rotheram-Borus, Lightfoot, & Shen, 1999; Rubin et al. 2011) . Some causal factors are potentially modifiable, including lack of emotional and social When taken as a elvitegravir/cobicistat/FTC/tenofovir fixed dose 'quad' formulation (German, Wang, Warren, & Kearney, 2011) .
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support, especially from the partner, intimate partner violence, ineffective coping and a history of psychiatric/depressive symptoms (Areias, Kumar, Barros, & Figueiredo, 1996; Bernatsky, Souza, & De Jong, 2007; Blaney et al., 2004; Cutrona, 1984; Gotlib, Whiffen, Wallace, & Mount, 1991; Hartley et al., 2011; Herbert & Cohen, 1993; Hobfoll, Ritter, Lavin, Hulsizer, & Cameron, 1995; Ross, Sawatphanit, & Zeller, 2009; Rubin et al., 2011) . Evidence indicating an association between perinatal depression and adverse obstetric and infant developmental outcomes is conflicting. Studies have linked perinatal depression with obstetric complications, neonatal faltering growth, and learning disorders (Alder, Fink, Bitzer, Ho¨sli, & Holzgreve, 2007; O'Brien, Heycock, Hanna, Jones, & Cox, 2004) . Others have reported a lack of association (Evans, Heron, Francomb, Oke, & Golding, 2001; Hartley et al., 2011; Kapetanovic et al., 2009) .
Breastfeeding
Several conflicting guidelines on HIV and breastfeeding have been published (Table 5) . ART can reduce the risk of MTCT via breast milk by over 50% (Kumwenda et al., 2008) . While breastfeeding with ART prophylaxis is not as effective as formula feeding in preventing MTCT, lower infant mortality rate with breastfeeding and comparable HIV-free survival for both feeding methods at 18 months have been reported. Therefore, exclusive breastfeeding is recommended in resource-poor countries (Thior et al., 2006; WHO, 2010) .
In some communities, a mother risks revealing her HIV status by not breastfeeding (Morgan, Masaba, Nyikuri, & Thomas, 2010) , and becoming a target for discrimination. For this reason, some guidelines now recommend supporting women in breastfeeding while taking ART if necessary (BHIVA & CHIVA, 2010; UNICEF, 2009 ). Issues in motherhood including stigma, discrimination, perinatal depression and emotional well-being and
Optimal method of infant feeding.
Conclusions
Working towards answering the many questions around reproductive and maternal health and emotional well-being both during and post-pregnancy in WLWH will help us optimise the health care for WLWH around the world. Addressing these gaps in the literature will direct the development of revised practice guidelines reflecting the specific needs of WLWH.
